Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B96 / ENGOT-ov65: Pembrolizumab vs placebo plus paclitaxel with or without bevacizumab in platinum-resistant recurrent ovarian cancer
2020-005027-37Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Pembrolizumab + paclitaxel ± bevacizumab with Placebo + paclitaxel ± bevacizumab (2 arms). Primary endpoint: Progression-free Survival (PFS) per RECIST 1.1 by investigator. Started Sep 2021; status: active.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2020-005027-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005027-37.